TRANFAL

PTO/SB/17 (10-03) Approved for use through 07/31/2006. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to re-

### **FEE TRANSMITTAL** for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

✓ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

<b>(2)</b>	65.	00
120)	oo.	vv

SDOILE RO & CONJECTION OF THE	
C	omplete if Known
Application Number	10/612,118
Filing Date	07/02/2003
First Named Inventor	DREON, Darlene M.
Examiner Name	unknown
Art Unit	1614
Attorney Docket No.	0125-UTL

Telephone 408-654-5830

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)			
Check Credit card Money Other None	3. ADDITIONAL FEES			
Clear College College College	Large Entity   Small Entity			
Deposit Account:	Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	e Paid		
Deposit Account 50-2247		5.00		
Number Deposit On till an Other representationals	1052 50 2052 25 Surcharge - late provisional filing fee or			
Deposit Account Name	cover sheet			
The Director is authorized to: (check all that apply)	1053 130 1053 130 Non-English specification 1812 2,520 1812 2,520 For filing a request for ex parts reexamination			
Charge fee(s) indicated below Credit any overpayments	1804 920* 1804 920* Requesting publication of SIR prior to	l		
Charge any additional fee(s) or any underpayment of fee(s)	Examiner action			
Charge fee(s) indicated below, except for the filing fee	1805 1,840" 1805 1,840" Requesting publication of SIR after Examiner action			
to the above-identified deposit account.	1251 110 2251 55 Extension for reply within first month			
FEE CALCULATION	1252 420 2252 210 Extension for reply within second month			
1. BASIC FILING FEE	1253 950 2263 475 Extension for reply within third month			
Large Entity Small Entity  Fee Fee Fee Fee Fee Fee Description Fee Paid	1254 1,480 2254 740 Extension for reply within fourth month			
Code (5) Code (5)	1255 2,010 2255 1,005 Extension for reply within fifth month			
1001 770 2001 385 Utility filing fee	1401 330 2401 165 Notice of Appeal	<u></u>		
1002 340 2002 170 Design filing fee	1402 330 2402 165 Filing a brief in support of an appeal			
1000 000	1403 290 2403 145 Request for oral hearing			
1004 770 2004 385 Reissue hing ree	1451 1,510 1451 1,510 Petition to institute a public use proceeding			
SUBTOTAL (1) (\$)	1452 110 2452 55 Petition to revive - unavoidable	<del></del>		
	1453 1,330 2463 665 Petition to revive - unintentional			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	_ · · · · · · · · · · · · · · · · · · ·			
Extra Claims below Fee Paid	11 1			
Total Claims	1 1503 640 2503 320 Plant issue fee			
Claims	1480 130 1460 130 Petitions to the Commissioner			
Multiple Dependent	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)			
Large Entity   Small Entity Fee Fee Fee Fee Fee Description	1806 180 1806 180 Submission of Information Disclosure Stmt			
Code (\$) Code (\$)	property (times number of properties)			
1202 18 2202 9 Claims in excess of 20	1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))			
1201 86 2201 43 Independent claims in excess or 3 1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 2810 385 For each additional invention to be			
1204 86 2204 43 ** Relasue independent claims	examined (37 CFR 1.129(b))  1801 770 2801 385 Request for Continued Examination (RCE)			
1205 18 2205 9 ** Reissue claims in excess of 20	1802 900 1802 900 Request for expedited examination of a design application			
and over original patent	Other fee (specify)			
SUBTOTAL (2) (\$)	"Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 65.00			
**or number previously paid, if greater; For Reissues, see above	(Complete (# applicable))			

Michelle Y. Walker Name (Print/Type) 10/07/2003 Signature WARNING: Information on this form may become public. Credit card Information should not

be included on this form. Provide credit card information and authorization on PTO-2038. This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Registration No.

53,903

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SUBMITTED BY

### COMBINED DECLARATION . AND POWER OF ATTORNEY

Case No 0125-UTL

As a below named joint inventor, each of us hereby declares as follows:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

# Composition and Methods for Treatment and/or Amelioration of Premenstrual Symptoms and for Reduction of Inflammatory Biomarkers in Female Subjects

the specification of which is filed herewith, attorney docket No. 0125-UTL.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information of which I am aware that is material to the patentability of this application in accordance with 37 CFR 1.56(a).

I do not know and do not believe: that this invention was ever known or used in the United States of America before our invention thereof; that this invention was patented or described in any printed publication in any country before our invention thereof or more than one year prior to this application; that this invention was in public use or on sale in the United States of America more than one year prior to this application; that this invention has been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application; nor that any application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns.

I hereby appoint the following attorneys/agents to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith:

Carol Stratford, Registration No. 34,444 Gloria Pfister, Registration No. 45,642 Michelle Y. Walker, Registration No. 53,903

Direct all telephone calls to -Michelle Walker at (408) 654-5830 ex. 179.

Address all correspondence to: Michelle Y. Walker Galileo Pharmaceuticals, Inc. 5301 Patrick Henry Drive, Santa Clara, California 95054

#### 6/ \$

## COMBINED DECLARATION AND POWER OF ATTORNEY

Case No 0125-UTL

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

First Joint Inventor: Darlene M. Dreon

		2	ael	ere	0	$\gg$	70
<del>-</del>	 -						

7/7/03

Inventor's signature

Date

Country of Citizenship

Residence:

United States of America Menlo Park, California

Post Office Address:

961 Lucky Ave, Menlo Park, CA 94025

Second Joint Inventor: Stephen Dodge Phinney

Inventor's signature

Date

Country of Citizenship:

**United States of America** 

Residence:

Elk Grove, CA

Post Office Address:

6108 Boothbay Court, CA 95758

## COMBINED DECLARATION AND POWER OF ATTORNEY

Case No 0125-UTL

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

First Joint Inventor: Darlene M. Dreon

Inventor's signature

Date

Country of Citizenship

Residence:

United States of America Menlo Park, California

Post Office Address:

961 Lucky Ave, Menlo Park, CA 94025

Second Joint Inventor: Stephen Dodge Phinney

Inventor's signature

Country of Citizenship:

Residence:

Post Office Address:

United States of America

Elk Grove, CA

6108 Boothbay Court, CA 95758